Table 2.
Frequency (%) | N | Histology | Method | Study | |
---|---|---|---|---|---|
North Africa | |||||
Algeria | 39.6 | 58 | NSCLC | Sanger | This study |
Morocco | 21 | 120 | ADC | TaqMan & Sanger | Errihani et al. |
Tunisia | 5.5 | 73 | ADC | Sanger | Dhieb et al. |
44 | 50 | ADC | IHC | Mraihi et al. | |
11.5 | 26 | ADC | ARMS/Scorpion | Arfaoui et al. | |
Middle East | |||||
Gulf region | 28.7 | 230 | NSCLC | qPCR | Jazieh et al. |
Levant region | 15.6 | 205 | ADC | ARMS/Scorpion | Tfayli et al. |
Lebanon | 11.9 | 201 | Non-SqCC | ARMS/Scorpion | Naderi et al. |
8.5 | 106 | ADC | ARMS/Scorpion | Fakhruddin et al. | |
Turkey | 16.7 | 959 | NSCLC | qPCR | Tezel et al. |
32.3 | 300 | ADC | Pyrosequencing | Demiray et al. | |
42.6 | 48 | NSCLC | Sanger | Unal et al. |
ARMS, Amplification-refractory mutation system; IHC, Immunohistochemistry; qPCR, Quantitative PCR.